Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy
© 2015 by the Society for Experimental Biology and Medicine Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to selectively induce apoptotic cell death in various tumor cells by engaging its death-inducing receptors (TRAIL-R1 and TRAIL-R2). This property has led to the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
SAGE Publications Inc.
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/5659 |
| _version_ | 1848744858511998976 |
|---|---|
| author | Dai, X. Zhang, J. Arfuso, Frank Chinnathambi, A. Zayed, M. Alharbi, S. Kumar, A. Ahn, K. Sethi, G. |
| author_facet | Dai, X. Zhang, J. Arfuso, Frank Chinnathambi, A. Zayed, M. Alharbi, S. Kumar, A. Ahn, K. Sethi, G. |
| author_sort | Dai, X. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2015 by the Society for Experimental Biology and Medicine Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to selectively induce apoptotic cell death in various tumor cells by engaging its death-inducing receptors (TRAIL-R1 and TRAIL-R2). This property has led to the development of a number of TRAIL–receptor agonists such as the soluble recombinant TRAIL and agonistic antibodies, which have shown promising anticancer activity in preclinical studies. However, besides activating caspase-dependent apoptosis in several cancer cells, TRAIL may also activate nonapoptotic signal transduction pathways such as nuclear factor-kappa B, mitogen-activated protein kinases, AKT, and signal transducers and activators of transcription 3, which may contribute to TRAIL resistance that is being now frequently encountered in various cancers. TRAIL resistance can be overcome by the application of efficient TRAIL-sensitizing pharmacological agents. Natural compounds have shown a great potential in sensitizing cells to TRAIL treatment through suppression of distinct survival pathways. In this review, we have summarized both apoptotic and nonapoptotic pathways activated by TRAIL, as well as recent advances in developing TRAIL–receptor agonists for cancer therapy. We also briefly discuss combination therapies that have shown great potential in overcoming TRAIL resistance in various tumors. |
| first_indexed | 2025-11-14T06:08:09Z |
| format | Journal Article |
| id | curtin-20.500.11937-5659 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:08:09Z |
| publishDate | 2015 |
| publisher | SAGE Publications Inc. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-56592018-03-29T09:05:22Z Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Dai, X. Zhang, J. Arfuso, Frank Chinnathambi, A. Zayed, M. Alharbi, S. Kumar, A. Ahn, K. Sethi, G. © 2015 by the Society for Experimental Biology and Medicine Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to selectively induce apoptotic cell death in various tumor cells by engaging its death-inducing receptors (TRAIL-R1 and TRAIL-R2). This property has led to the development of a number of TRAIL–receptor agonists such as the soluble recombinant TRAIL and agonistic antibodies, which have shown promising anticancer activity in preclinical studies. However, besides activating caspase-dependent apoptosis in several cancer cells, TRAIL may also activate nonapoptotic signal transduction pathways such as nuclear factor-kappa B, mitogen-activated protein kinases, AKT, and signal transducers and activators of transcription 3, which may contribute to TRAIL resistance that is being now frequently encountered in various cancers. TRAIL resistance can be overcome by the application of efficient TRAIL-sensitizing pharmacological agents. Natural compounds have shown a great potential in sensitizing cells to TRAIL treatment through suppression of distinct survival pathways. In this review, we have summarized both apoptotic and nonapoptotic pathways activated by TRAIL, as well as recent advances in developing TRAIL–receptor agonists for cancer therapy. We also briefly discuss combination therapies that have shown great potential in overcoming TRAIL resistance in various tumors. 2015 Journal Article http://hdl.handle.net/20.500.11937/5659 10.1177/1535370215579167 SAGE Publications Inc. restricted |
| spellingShingle | Dai, X. Zhang, J. Arfuso, Frank Chinnathambi, A. Zayed, M. Alharbi, S. Kumar, A. Ahn, K. Sethi, G. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy |
| title | Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy |
| title_full | Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy |
| title_fullStr | Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy |
| title_full_unstemmed | Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy |
| title_short | Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy |
| title_sort | targeting tnf-related apoptosis-inducing ligand (trail) receptor by natural products as a potential therapeutic approach for cancer therapy |
| url | http://hdl.handle.net/20.500.11937/5659 |